Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 March 2006

Results of severe sepsis treatment program using recombinant human activated protein C in Poland.

Andrzej Kübler, Ewa Mayzner-Zawadzka, Grażyna Durek, Wojciech Gaszyński, Ewa Karpel, Małgorzata Mikaszewska-Sokolewicz, Paweł Majak

Med Sci Monit 2006; 12(3): CR107-112 :: ID: 447107


Background: Recombinant human activated protein C (drotrecogin alfa [activated]- DAA) demonstrated in Phase III controlled clinical studies significant reduction of mortality in patientswith severe sepsis and high risk of death. The aim of the study was to assess the therapeutic efficacyof DAA in patients included in the National Severe Sepsis Register in Poland. Material/Methods: The analysisincluded 3233 cases of severe sepsis reported between 04.2003 and 11.2005. 302 patients (9.3%) were treatedwith DAA. The clinical course of the disease in DAA and non-DAA treatment groups was compared. Logisticregression models for the effects of independent variables on the risk of death (dependent variable)were developed. Results: In the patients treated with DAA, the relative risk of death was lower by 31%than in those who were not treated. In a multivariate logistic regression model, the use of DAA was,independently of the patient's age, severity of the clinical condition and type of organ dysfunction,the most significant mortality-reducing factor in severe sepsis. Conclusions: The use of DAA in the treatmentof severe sepsis proved to be a very effective method of mortality reduction. Controlled nationwide surveillanceprogram contributed to its effective utilization. The National Severe Sepsis Register proved to be avery useful instrument for assessment of the course of the disease and treatment efficacy.

Keywords: Sepsis - mortality, Registries, Recombinant Proteins - therapeutic use, Protein C - therapeutic use, Population Surveillance, Poland - epidemiology, Multivariate Analysis, Anti-Infective Agents - therapeutic use, Logistic Models, Intensive Care Units - statistics & numerical data, Hemorrhage - chemically induced, Evaluation Studies as Topic, APACHE

Add Comment 0 Comments

486 3


01 June 2023 : Editorial  

Editorial: Infectious Disease Surveillance Using Artificial Intelligence (AI) and its Role in Epidemic and Pandemic Preparedness

Dinah V. Parums
Science Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA

DOI: 10.12659/MSM.941209

Med Sci Monit 2023; 29:e941209


In Press

08 Jun 2023 : Clinical Research  

Risk Factors for New Vertebral Compression Fracture After Percutaneous Vertebral Augmentation: A Retrospect...

Med Sci Monit In Press; DOI: 10.12659/MSM.940134  

08 Jun 2023 : Clinical Research  

A Nomogram for Identifying HR+/Her2- Breast Cancer Patients with Positive Sentinel Lymph Nodes and Omitted ...

Med Sci Monit In Press; DOI: 10.12659/MSM.940124  

08 Jun 2023 : Clinical Research  

Burden of COVID-19 on Mental Health of Resident Doctors in Poland

Med Sci Monit In Press; DOI: 10.12659/MSM.940208  

08 Jun 2023 : Clinical Research  

Risk Prediction for Rapidly Progressive Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis: Th...

Med Sci Monit In Press; DOI: 10.12659/MSM.940251  

Most Viewed Current Articles

13 Nov 2021 : Clinical Research  

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788


30 Dec 2021 : Clinical Research  

Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...

DOI :10.12659/MSM.935379

Med Sci Monit 2021; 27:e935379

08 Mar 2022 : Review article  

A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...

DOI :10.12659/MSM.936292

Med Sci Monit 2022; 28:e936292

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750